ArticleBlood advances2025

TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALL.

Ibrahim Aldoss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.